1313MO Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patients (pts) with stage IIIB–IV non-small-cell lung cancer (NSCLC) with previous anti-PD-(L)1 therapy

Benjamin Besse, Antoine Italiano, Sophie Cousin, G. Ruiter, Enriqueta Felip, Eduardo Castañón Álvarez, Suresh S. Ramalingam, Christian Rolfo, David R. Spigel, Diana Andrew, Soyun Cho, Teresa Collins, Aaron R. Hansen, George Hawkins, Raffael Kurek, Natalia Ceaicovscaia, Michele Petruzzelli, Emma Dean, Adrian G. Sacher